HCG Education
What is HCG? A Complete Guide to Human Chorionic Gonadotropin
Human chorionic gonadotropin (HCG) is a glycoprotein hormone that mimics the action of luteinizing hormone (LH) in the body. It is naturally produced by the placenta during pregnancy, but in the performance enhancement and hormone therapy space, it is used for an entirely different purpose: stimulating the testes to produce testosterone. HCG is one of the most widely used compounds during and after anabolic steroid cycles, and it plays a critical role in testosterone replacement therapy protocols where preserving fertility is a priority. Products like GENX-HCG are designed specifically for this market.
The Molecular Structure of HCG
HCG is a heterodimeric glycoprotein, meaning it is made up of two distinct protein chains (subunits) that are joined together. These are called the alpha subunit and the beta subunit.
The alpha subunit of HCG is identical to the alpha subunit found in three other human glycoprotein hormones: luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). All four hormones share this same 92 amino acid alpha chain. What makes each hormone different is its beta subunit, which is unique to each one and determines which receptors the hormone can bind to and what biological effects it produces.
The beta subunit of HCG shares over 85% sequence identity with the beta subunit of LH through the first 113 amino acids. This structural similarity is why HCG can bind to and activate the same receptor as LH. However, the beta-HCG chain contains an additional carboxy-terminal peptide (CTP) of approximately 24 amino acids that LH does not have. This CTP contains four O-linked glycosylation sites that protect the molecule from rapid metabolic clearance. This single structural difference is responsible for the dramatically different half-life between the two hormones: HCG persists in the bloodstream for roughly 29 to 37 hours, while LH is cleared in approximately 20 to 30 minutes.
How HCG Works: The LHCG Receptor and Testosterone Production
HCG exerts its effects by binding to the luteinizing hormone/choriogonadotropin receptor (LHCGR), a G protein-coupled receptor found primarily on the surface of Leydig cells in the testes. This is the same receptor that LH binds to. When HCG occupies the receptor, it triggers the same intracellular signalling cascade that LH would, activating the cAMP/PKA pathway inside the Leydig cell.
This signalling cascade initiates steroidogenesis, the process by which cholesterol is converted into testosterone within the Leydig cell. The key step involves the upregulation of steroidogenic acute regulatory protein (StAR), which transports cholesterol from the outer mitochondrial membrane to the inner membrane where the first enzymatic conversion takes place. From there, the cholesterol is processed through a series of enzymatic steps (involving CYP11A1, 3β-HSD, CYP17A1, and 17β-HSD) to produce testosterone.
In simpler terms: HCG tells the Leydig cells to produce testosterone. It does this by mimicking the signal that LH would normally deliver from the pituitary gland. The Leydig cells cannot distinguish between HCG and LH at the receptor level, so they respond the same way. This is why HCG is so effective at maintaining or restarting testosterone production when the body’s own LH output has been suppressed.
One additional effect worth understanding: HCG also stimulates aromatase activity within Leydig cells, which means it increases the conversion of testosterone to estradiol (an estrogen). This is a documented physiological response, not a side effect of poor quality HCG. At moderate doses the estrogen increase is usually manageable, but at high doses or with prolonged use, some users may need an aromatase inhibitor to control estrogen levels. This is particularly relevant during post-cycle therapy, when hormonal balance is already in flux.
HCG Pharmacokinetics: Half-Life, Absorption, and Metabolism
Understanding the pharmacokinetics of HCG explains why it is dosed differently from LH and why injection frequency matters for maintaining stable testosterone levels.
Research comparing subcutaneous and intramuscular HCG injection has shown that intramuscular injection produces higher peak concentrations and a larger total area under the curve (AUC) than subcutaneous injection. However, subcutaneous injection is the preferred route for most users because it is easier to self-administer, uses a smaller needle, and still produces therapeutically effective serum levels. The practical significance of the route difference is modest for the doses typically used in PCT and on-cycle protocols.
The long half-life of HCG is what makes it practical as a therapeutic agent. Because it persists in the bloodstream for over a day, it does not need to be injected daily. Most protocols call for injections two to three times per week, which maintains relatively stable Leydig cell stimulation without the need for frequent dosing.
Why HCG is Used in Post-Cycle Therapy
During an anabolic steroid cycle, the exogenous hormones signal to the hypothalamus and pituitary gland that testosterone levels are already elevated. In response, the pituitary reduces or completely stops its production of LH and FSH, a process known as negative feedback suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Without LH signalling, the Leydig cells in the testes receive no instruction to produce testosterone. Over time, the lack of stimulation causes the Leydig cells to atrophy (shrink), the testes reduce in size, and intratesticular testosterone drops to near-zero levels.
When the steroid cycle ends, the exogenous hormones clear the system, and the HPG axis needs to restart its natural signalling. This recovery process can take weeks or months, during which testosterone levels remain low. The user experiences symptoms of hypogonadism including muscle loss, fat gain, fatigue, mood changes, and impaired libido. This is the recovery window that post-cycle therapy is designed to shorten.
HCG addresses this directly by bypassing the suppressed pituitary and stimulating the Leydig cells at the receptor level. It tells them to produce testosterone even though the pituitary is not yet sending LH. This restores intratesticular testosterone, reverses testicular atrophy, and provides a bridge of testosterone production while the HPG axis recovers. HCG is typically used during the first phase of PCT, followed by selective estrogen receptor modulators (SERMs) like Clomid (clomiphene) or Nolvadex (tamoxifen) which work at the hypothalamic and pituitary level to restart endogenous LH production.
HCG During a Steroid Cycle: Preventing the Damage Before It Happens
An increasingly common approach is to use HCG throughout the steroid cycle at a lower dose rather than waiting until PCT. The rationale is preventive: if you keep the Leydig cells active and stimulated during the cycle, they do not atrophy, testicular volume is maintained, and the transition to PCT is significantly easier because the testes are already functional when the exogenous hormones clear.
On-cycle HCG doses are typically lower than PCT doses, commonly in the range of 250 to 500 IU administered two to three times per week. This is enough to maintain Leydig cell function without causing excessive estrogen conversion (which higher doses can provoke through increased aromatase activity). The goal is maintenance, not maximal stimulation. Users who run HCG on-cycle consistently report easier PCT recovery compared to those who only introduce HCG after the cycle has ended.
HCG in Testosterone Replacement Therapy
Men on testosterone replacement therapy (TRT) face the same HPG axis suppression as steroid users. The exogenous testosterone signals the pituitary to stop producing LH, which means the testes stop producing their own testosterone and, critically, stop producing the intratesticular testosterone that is required for spermatogenesis (sperm production). For men on TRT who want to preserve fertility, this is a significant problem.
HCG solves this by providing the Leydig cell stimulation that the suppressed pituitary no longer delivers. It maintains intratesticular testosterone at levels sufficient to support Sertoli cell function and ongoing spermatogenesis. Many TRT clinics prescribe HCG alongside testosterone as standard practice for men who wish to maintain fertility. Without HCG, prolonged TRT can lead to azoospermia (complete absence of sperm) which may take months to reverse after discontinuing treatment.
Reconstitution and Storage
HCG is supplied as a lyophilised (freeze-dried) powder and must be reconstituted with bacteriostatic water before injection. The reconstitution process is the same as for GenXtropin HGH: add the water slowly against the glass wall of the vial, swirl gently, and never shake. Our step by step reconstitution guide covers the full process in detail with dose calculation tables.
Once reconstituted, HCG should be refrigerated at 2 to 8 degrees Celsius and used within 30 days. Unreconstituted vials should also be stored in the refrigerator and kept away from light. Do not freeze reconstituted HCG. If the solution appears cloudy or contains visible particles after mixing, discard the vial. For full delivery details on GENX-HCG, visit the shipping and returns page.
HCG FAQ
Why does HCG last so much longer in the body than LH?
+
HCG and LH share over 85% sequence identity in their beta subunits, but the beta chain of HCG contains an additional carboxy-terminal peptide (CTP) of approximately 24 amino acids that LH does not have. This CTP carries O-linked glycosylation sites that shield the molecule from rapid clearance by the kidneys. The result is a terminal half-life of 29 to 37 hours for HCG compared to roughly 20 to 30 minutes for LH. This is why HCG can be injected two to three times per week while endogenous LH is released in frequent pulses by the pituitary.
Can HCG increase estrogen levels?
+
Yes. HCG stimulates aromatase activity within Leydig cells, which increases the conversion of testosterone to estradiol. This is a normal physiological response to HCG stimulation, not a sign of poor quality product. At moderate doses (250 to 500 IU two to three times per week), the estrogen increase is usually manageable. At higher doses or with prolonged use, estrogen levels can rise enough to cause symptoms like water retention or gynecomastia. Some users manage this with a low dose aromatase inhibitor during periods of HCG use.
Should I use HCG during a cycle or only during PCT?
+
Using HCG during the cycle at a low maintenance dose is generally considered the better approach. It keeps the Leydig cells active and prevents testicular atrophy while the cycle is running, which makes the transition to PCT significantly easier. If HCG is only introduced during PCT after weeks or months of complete Leydig cell suppression, the cells need to be “reawakened” first, which adds time and complexity to recovery. On-cycle use at 250 to 500 IU two to three times per week is a common protocol that maintains function without excessive estrogen conversion.
Can I use HCG and HGH at the same time?
+
Yes. HCG and HGH serve completely different purposes and work through separate pathways. HCG stimulates the LHCG receptor on Leydig cells to produce testosterone. Somatropin (the active substance in GenXtropin HGH) binds to growth hormone receptors and stimulates IGF-1 production. The two do not interfere with each other, and they are frequently used together by people in the bodybuilding and hormone optimisation space. Both products are available through GenXtropin UK.
Looking for HCG?
GENX-HCG is available from the official GenXtropin UK store alongside GenXtropin HGH 100IU and GENX-MT2 nasal spray. All orders ship with Royal Mail tracking and discreet packaging. Visit the reviews page to read customer feedback.
View GENX-HCG